Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial
By Adria Calatayud
Roche Holding shares rose after the Swiss pharmaceutical giant said a drug candidate achieved positive results for weight loss in an early-stage clinical trial in adults with obesity.
The company joined the race for drugs to treat obesity and diabetes through its purchase of Carmot Therapeutics, seeking a slice of the market that has lifted the fortunes of pharma groups such as Wegovy and Ozempic maker Novo Nordisk and Mounjaro and Zepbound maker Eli Lilly.
The obesity drug candidate Roche bought as part of its Carmot deal--known as CT-388--showed positive results in a phase 1 study, by leading to significant weight loss in healthy adults with obesity compared to placebo, the company said Thursday.
At 0743 GMT, Roche shares traded 3.8% higher at CHF236.10, but remained down 3.4% since the start of the year.
The drug, a once weekly subcutaneous injectable under development for the treatment of obesity and type 2 diabetes, was well tolerated and no new or unexpected safety signals were detected, Roche said.
The results of the trial underscore the drug's potential to become a therapy with durable weight loss and glucose control, said Levi Garraway, Roche's chief medical officer and head of global product development.
While the phase 1 data looks encouraging, Roche has still a long way to go and more details are likely needed to assess the drug's position and commercial potential in a highly competitive market, Jefferies analysts wrote in a note to clients.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
May 16, 2024 04:07 ET (08:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now